Your session is about to expire
← Back to Search
MTM + CHW Support for Type 2 Diabetes (ENRxICH Trial)
N/A
Recruiting
Led By Olayinka Shiyanbola, PhD, BPharm
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months and 12 months
Awards & highlights
ENRxICH Trial Summary
This trial aims to improve diabetes self-management in Black & Hispanic adults with type 2 diabetes, by exploring the best way to use medicines & support from pharmacists & Community Health Workers.
Who is the study for?
This trial is for Black and Hispanic adults aged 18-90 with type 2 diabetes, who speak English or Spanish. They must live in the study area, have a phone, take diabetes medication from the study pharmacy, and have an HbA1c of at least 8%. They can't join if they've had similar medicine management support recently or are in another program.Check my eligibility
What is being tested?
The study tests four approaches to improve diabetes self-management: usual care; added pharmacist support for medicine management; help from a Community Health Worker (CHW) with life challenges; or both pharmacist and CHW support. Participants will be randomly placed into one of these groups.See study design
What are the potential side effects?
Since this trial focuses on management approaches rather than new medications, side effects may not be directly related to treatments but could include stress or discomfort due to changes in routine healthcare practices.
ENRxICH Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months and 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months and 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in mean hemoglobin A1c score
Secondary outcome measures
Change in medication adherence - medication refill
Mean scores on the Adherence to Refills and Medications Scale for Diabetes
ENRxICH Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Medication Therapy Management (MTM)Experimental Treatment1 Intervention
Group II: MTM + CHWExperimental Treatment2 Interventions
Group III: Community Health Worker (CHW)Experimental Treatment1 Intervention
Group IV: Usual CareActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CHW
2020
N/A
~200
MTM
2015
N/A
~1420
Find a Location
Who is running the clinical trial?
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,381 Previous Clinical Trials
4,315,186 Total Patients Enrolled
106 Trials studying Diabetes
138,412 Patients Enrolled for Diabetes
University of Wisconsin, MadisonLead Sponsor
1,196 Previous Clinical Trials
3,162,035 Total Patients Enrolled
6 Trials studying Diabetes
169 Patients Enrolled for Diabetes
Olayinka Shiyanbola, PhD, BPharmPrincipal InvestigatorUniversity of Wisconsin, Madison
2 Previous Clinical Trials
61 Total Patients Enrolled
1 Trials studying Diabetes
30 Patients Enrolled for Diabetes
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18-90 years old, identify as Black or Hispanic, and have type 2 diabetes. I can speak or read English or Spanish.I have a caregiver who makes key decisions about my health care.I am on diabetes medication that I get from the study's pharmacy.
Research Study Groups:
This trial has the following groups:- Group 1: Usual Care
- Group 2: Medication Therapy Management (MTM)
- Group 3: Community Health Worker (CHW)
- Group 4: MTM + CHW
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger